• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development

Vaccine Boosting CAR-T Cell Therapy Solutions against Solid Tumors

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Combination of CAR-T cell Therapy with Vaccines

CAR-T cell therapy is a promising immunotherapy that uses genetically engineered T cells to recognize and destroy cancer cells. However, there are challenges with this therapy, including limited effectiveness in solid tumors and the potential for relapse. To address these, researchers are exploring combination strategies with other immunotherapies, such as vaccines, to boost the efficacy of CAR-T cell therapy. Vaccines work by stimulating the immune system to recognize and attack specific targets, such as cancer cells. The combination of CAR-T cell therapy with vaccines can enhance the targeting and killing of cancer cells of CAR-T cells, as well as boost the memory and persistence of CAR-T cells within the body. This combination approach may also help to target a broader range of cancer antigens, reducing the risk of tumor escape.

Fig.1 The mechanism of amph-vax boosting CAR-T cells.¹

Our Vaccine Platforms for Boosting CAR-T Cell Therapy

Various vaccines are designed to stimulate the immune system and enhance the efficacy of CAR-T cell therapy. At Creative Biolabs, we aim to provide solutions that optimize the therapeutic potential of this innovative combination treatment approach. Our team of experts is committed to delivering high-quality vaccines tailored to meet the specific needs of CAR-T cell therapy.

• Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions

Peptide-DC vaccine is a type of therapeutic cancer vaccine that involves using DCs loaded with tumor-specific peptides that are presented on MHC molecules to activate CAR-T cells and enhance their ability to recognize and target cancer cells that express the specific tumor peptides. Our service involves the development and production of peptide-DC vaccines for boosting pMHC-directed CAR-T cell therapy. Our peptide-DC vaccine services include peptide selection, DC loading optimization, quality control, and functional analysis in vitro and in vivo.

• Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions

Amph-ligands contain antigens to activate the CAR-T cells and long tails of lipids to bind to free albumin in the blood. Amph-ligands have been successfully used as a tumor vaccine-boosting strategy in the treatment of CAR-T cells. At Creative Biolabs, we are committed to developing innovative amph-ligand vaccines to enhance the potency of CAR-T cell therapies.

• RNA Vaccine Boosting CAR-T Cell Solutions

RNA vaccines can stimulate the immune system to recognize and attack cancer cells by delivering tumor-specific antigens encoded in RNA. By delivering stimulatory signals to CAR-T cells, RNA vaccines can enhance their ability to kill cancer cells and overcome mechanisms of immune evasion. At Creative Biolabs, our experts offer customized RNA vaccines for boosting CAR-T cells, making them a promising option for personalized cancer treatment.

• Virus-based Vaccine Boosting CAR-T Cell Solutions

Virus-based vaccines use a live-attenuated or inactivated virus to trigger an immune response in the body. Combining virus-based vaccines with CAR-T cell therapy may help enhance the immune response and improve the overall efficacy of the CAR-T cells.

Reference

1. Ma, Leyuan, et al. "Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity." Cell 186.15 (2023): 3148-3165.